Restricted accessResearch articleFirst published online 2016-11-1
An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APP Swe Transgenic Mouse Model of Alzheimer’s Disease
Erythropoietin (EPO) is a cytokine known to have effective cytoprotective action in the brain, particularly in ischemic, traumatic, inflammatory, and neurodegenerative conditions. We previously reported the neuroprotective effect of a low sialic form of EPO, Neuro-EPO, applied intranasally in rodent models of stroke or cerebellar ataxia and in a non-transgenic mouse model of Alzheimer’s disease (AD). Here we analyzed the protective effect of Neuro-EPO in APPSwe mice, a reference transgenic mouse model of AD. Mice were administered 3 times a day, 3 days in the week with Neuro-EPO (125, 250 μg/kg) intranasally, between 12 and 14 months of age. Motor responses, general activity, and memory responses were analyzed during and after treatment. The deficits in spontaneous alternation, place learning in the water-maze, and novel object recognition observed in APPSwe mice were alleviated by the low dose of Neuro-EPO. Oxidative stress, neuroinflammation, trophic factor levels, and a synaptic marker were analyzed in the hippocampus or cortex of the animals. The increases in lipid peroxidation or in GFAP and Iba-1 contents in APPSwe mice were significantly reduced after Neuro-EPO. Activation of intrinsic and extrinsic apoptotic pathways was analyzed. The increases in Bax/Bcl-2 ratio, TNFα, or Fas ligand levels observed in APPSwe mice were reduced by Neuro-EPO. Finally, immunohistochemical and ELISA analyses of Aβ1–42 levels in the APPSwe mouse cortex and hippocampus showed a marked reduction in Aβ deposits and in soluble and insoluble Aβ1–42 forms. This study therefore confirmed the neuroprotective activity of EPO, particularly for an intranasally deliverable formulation, devoid of erythropoietic side effects, in a transgenic mouse model of AD. Neuro-EPO alleviated memory alterations, oxidative stress, neuroinflammation, apoptosis induction, and amyloid load in 14-month-old APPSwe mice.
RabieT, MartiHH (2008) Brain protection by erythropoietin: A manifold task. Physiology (Bethesda)2, 263–274.
2.
DigicayliogluM, BichetS, MartiHH, WengerRH, RivasLA, BauerC, GassmannM (1995) Localization of specific erythropoietin binding-sites in defined areas of the mouse-brain. Proc Natl Acad Sci U S A92, 3717–3720.
3.
MorishitaE, MasudaS, NagaoM, YasudaY, SasakiR (1997) Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience76, 105–116.
4.
NadamJ, NavarroF, SanchezP, MoulinC, GeorgesB, LaglaineA, PequignotJM, MoralesA, RyvlinP, BezinL (2007) Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus. Neurobiol Dis25, 412–426.
5.
NagaiA, NakagawaE, ChoiHB, HatoriK, KobayashiS, KimSU (2001) Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol60, 386–392.
6.
SanchezPE, FaresRP, RissoJJ, BonnetC, BouvardS, Le-CavorsinM, GeorgesB, MoulinC, BelmeguenaiA, BodennecJ, MoralesA, PequignotJM, BaulieuEE, LevineRA, BezinL (2009) Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons. Proc Natl Acad Sci U S A106, 9848–9853.
7.
JubinskyPT, KrijanovskiOI, NathanDG, TavernierJ, SieffCA (1997) The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood90, 1867–1873.
8.
BrinesM, GrassoG, FiordalisoF, SfacteriaA, GhezziP, FratelliM, LatiniR, XieQW, SmartJ, Su-RickCJ, ProbeE, DiazD, GomezD, HandC, ColemanT, CeramiA (2004) Erythropoietin mediates tissue protection through an erythropoietin and comme β-subunit heteroreceptor. Proc Natl Acad Sci U S A101, 14907–14912.
BernaudinM, MartiHH, RousselS, DivouxD, NouvelotA, MacKenzieET, PetitE (1999) A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab19, 643–651.
14.
Hoynck van PapendrechtMA, JeekelH, BuschOR, MarquetRL (1992) Efficacy of recombinant erythropoietin for stimulating erythropoiesis after blood loss and surgery. An experimental study in rats. Eur J Surg158, 83–87.
15.
BrinesML, GhezziP, KeenanS, AgnelloD, de LanerolleNC, CeramiC, ItriLM, CeramiA (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A97, 10526–10531.
16.
CelikM, GökmenN, ErbayraktarS, AkhisarogluM, KonakcS, UlukusC, GencS, GencK, SagirogluE, CeramiA, BrinesM (2002) Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A99, 2258–2263.
17.
LiW, MaedaY, YuanRR, ElkabesS, CookS, DowlingP (2004) Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann Neurol56, 767–777.
18.
KumralA, BaskinH, GokmenN, YilmazO, GencK, GencS, TatliMM, DumanN, OzerE, OzkanH (2004) Selective inhibition of nitric oxide in hypoxic-ischemic brain model in newborn rats: Is it an explanation for the protective role of erythropoietin?Biol Neonate85, 51–54.
19.
LeistM, GhezziP, GrassoG, BianchiR, VillaP, FratelliM, SavinoC, BianchiM, NielsenJ, GerwienJ, KallunkiP, LarsenAK, HelboeL, ChristensenS, PedersenLO, NielsenM, TorupL, SagerT, SfacteriaA, ErbayraktarS, ErbayraktarZ, GokmenN, YilmazO, Cerami-HandC, XieQW, ColemanT, CeramiA, BrinesM (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science305, 239–242.
20.
GencS, ZadeoglulariZ, OnerMG, GencK, DigicaylioluM (2011) Intranasal erythropoietin therapy in nervous system disorders. Expert Opin Drug Deliv8, 19–32.
21.
ChongZZ, LiF, MaieseK (2005) Erythropoietin requires NF-κB and its nuclear translocation to prevent early and late apoptotic neuronal injury during β-amyloid toxicity. Curr Neurovasc Res2, 387–399.
22.
LiG, MaR, HuangC, TangQ, FuQ, LiuH, HuB, XiangJ (2008) Protective effect of erythropoietin on β-amyloid-induced PC12 cell death through antioxidant mechanisms. Neurosci Lett442, 143–147.
23.
MaR, XiongN, HuangC, TangQ, HuB, XiangJ, LiG (2009) Erythropoietin protects PC12 cells from β-amyloid25-35-induced apoptosis via PI3K/Akt signaling pathway. Neuropharmacology56, 1027–1034.
24.
ArabpoorZ, HamidiG, RashidiB, ShabrangM, AlaeiH, SharifiMR, SalamiM, DolatabadiHR, ReisiP (2012) Erythropoietin improves neuronal proliferation in dentate gyrus of hippocampal formation in an animal model of Alzheimer’s disease. Adv Biomed Res1, 50.
25.
LeeST, ChuK, ParkJE, JungKH, JeonD, LimJY, LeeSK, KimM, RohJK (2012) Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-β burden in Alzheimer’s disease models. J Neurochem120, 115–124.
26.
Armand-UgónM, AoE, MorenoJ, Riera-CordinaM, SánchezA, VegasE, FerrerI (2015) Memory improvement in the AbPP/PS1 mouse model of familial Alzheimer’s disease induced by carbamylated erythropoietin is accompanied by modulation of synaptic genes. J Alzheimers Dis45, 407–421.
27.
Garcia-RodríguezJC, Sosa-TestéI (2009) The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans. ScientificWorldJournal9, 970–981.
28.
RodríguezCruz Y, Mengana TámosY, Muñoz CernudaA, Subirós MartinesN, González-QuevedoA, Sosa TestéI, Garcia RodriguezJC (2010) Treatment with nasal neuro-EPO improves the neurological, cognitive, and histological state in a gerbil model of focal ischemia. ScientificWorldJournal10, 2288–2300.
29.
Garcia-RodríguezJC, Rodríguez-CruzY (2012) The therapeutic potential of Neuro-EPO administered nasally on acute cerebrovascular disease. Curr Psychopharmacol1, 228–232.
30.
MauriceT, LockhartBP, PrivatA (1996) Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction. Brain Res706, 181–193.
31.
LahmyV, MeunierJ, MalmströmS, NaertG, GivaloisL, KimSH, VillardV, VamvakidesA, MauriceT (2013) Blockade of Tau hyperphosphorylation and Aβ1-42 generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ1 receptor agonist, in a nontransgenic mouse model of Alzheimer’s disease. Neuropsychopharmacology38, 1706–1723.
32.
MauriceT, MustafaMH, DesrumauxC, KellerE, NaertG, de la C. García-BarcelóM, Rodríguez CruzY, Garcia RodríguezJC (2013) Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ25-35 nontransgenic mouse model of Alzheimer’s disease. J Psychopharmacol27, 1044–1057.
ChapmanPF, WhiteGL, JonesMW, Cooper-BlacketerD, MarshallVJ, IrizarryM, YounkinL, GoodMA, BlissTV, HymanBT, YounkinSG, HsiaoKK (1999) Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci2, 271–276.
35.
LanzTA, CarterDB, MerchantKM (2003) Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol Dis13, 246–253.
36.
JacobsenJS, WuCC, RedwineJM, ComeryTA, AriasR, BowlbyM, MartoneR, MorrisonJH, PangalosMN, ReinhartPH, BloomFE. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A103, 5161–5166.
37.
JungJH, AnK, KwonOB, KimHS, KimJH (2011) Pathway-specific alteration of synaptic plasticity in Tg2576 mice. Mol Cells32, 197–201.
38.
StewartS, CacucciF, LeverC (2011) Which memory task for my mouse? A systematic review of spatial memory performance in the Tg2576 Alzheimer’s mouse model. J Alzheimers Dis26, 105–126.
39.
WebsterSJ, BachstetterAD, NelsonPT, SchmittFA, Van EldikLJ (2014) Using mice to model Alzheimer’s dementia: An overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet5, 88.
40.
Sosa TestéI, García RodríguezJC, García SalmanJD, SantanaJ, Subirós MartínezN, González TrianaC, Rodríguez CruzY, Cruz RodríguezJ (2006) Intranasal administration of recombinant human erythropoietin exerts neuroprotective effects on post-ischemic brain injury in mongolian gerbils. Pharmacologyonline1, 100–112.
41.
PaxinosG, FranklinKBJ (2004) The mouse brain in stereotaxic coordinates, compact second edition, Elsevier Academic Press, London UK.
42.
MaieseK, HouJ, ChongZZ, ShangYC (2009) Erythropoietin, forkhead proteins, and oxidative injury: Biomarkers and biology. ScientificWorldJournal9, 1072–1104.
43.
SunZK, YangHQ, PanJ, ZhenH, WangZQ, ChenSD, DingJQ (2008) Protective effects of erythropoietin on tau phosphorylation induced by beta-amyloid. J Neurosci Res86, 3018–3027.
44.
CraftS, BakerLD, MontineTJ, MinoshimaS, WatsonGS, ClaxtonA, ArbuckleM, CallaghanM, TsaiE, PlymateSR, GreenPS, LeverenzJ, CrossD, GertonB (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol69, 29–38.
45.
Alcalá-BarrazaSR, LeeMS, HansonLR, McDonaldAA, FreyWH, McLoonLK (2010) Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target18, 179–190.
46.
van WoenselM, WauthozN, RosièreR, AmighiK, MathieuV, LefrancF, van GoolSW, de VleeschouwerS (2013) Formulations for intranasal delivery of pharmacological agents to combat brain disease: A new opportunity to tackle GBM?Cancer5, 1020–1048.
47.
FrautschySA, YangF, IrrizarryM, HymanB, SaidoTC, HsiaoK, ColeGM (1998) Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol152, 307–317.
48.
DongH, GoicoB, MartinM, CsernanskyCA, BertchumeA, CsernanskyJG (2004) Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress. Neuroscience127, 601–609.
49.
RothmanSM, HerdenerN, CamandolaS, TexelSJ, MughalMR, CongWN, MartinB, MattsonMP (2012) 3xTgAD mice exhibit altered behavior and elevated Aβ after chronic mild social stress. Neurobiol Aging33, 830.e1–830.e12.
50.
BrureauA, ZussyC, DelairB, OgierC, IxartG, MauriceT, GivaloisL (2013) Deregulation of HPA axis functions in an Alzheimer’s disease rat model. Neurobiol Aging34, 1426–1439.
51.
TringaliG, PozzoliG, LisiL, NavarraP (2007) Erythropoietin inhibits basal and stimulated corticotropin-releasing hormone release from the rat hypothalamus via anontranscriptional mechanism. Endocrinology148, 4711–4715.
52.
Castañeda-ArellanoR, Feria-VelascoAI, Rivera-CervantesMC (2014) Activity increase in EpoR and Epo expression by intranasal recombinant human erythropoietin (rhEpo) administration in ischemic hippocampi of adult rats. Neurosci Lett583, 16–20.
53.
OttC, MartensH, HassounaI, OliveiraB, ErckC, ZafeiriouMP, PeteriUK, HesseD, GerhartS, AltasB, KolbowT, StadlerH, KawabeH, ZimmermannWH, NaveKA, Schulz-SchaefferW, JahnO, EhrenreichH (2015) Widespread expression of erythropoietin receptor in brain and its induction by injury. Mol Med21, 803–815.
WangL, ZhangZ, WangY, ZhangR, ChoppM (2004) treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke35, 1732–1737.
56.
NaertG, IxartG, MauriceT, Tapia-ArancibiaL, GivaloisL (2011) Brain-derived neurotrophic factor and hypothalamic-pituitary-adrenal axis adaptation processes in a depressive-like state induced by chronic restraint stress. Mol Cell Neurosci46, 55–66.
57.
ZussyC, BrureauA, DelairB, MarchalS, KellerE, IxartG, NaertG, MeunierJ, ChevallierN, MauriceT, GivaloisL (2011) Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid β fragment in rats. Am J Pathol179, 315–334.
58.
Almaguer-MelianW, Mercerón-MartínezD, Delgado-OcañaS, Pavón-FuentesN, LedónN, BergadoJA (2016) EPO induces changes in synaptic transmission and plasticity in the dentate gyrus of rats. Synapse70, 240–252.
BaileyDM, LundbyC, BergRM, TaudorfS, RahmouniH, GutowskiM, MulhollandCW, SullivanJL, SwensonER, McEnenyJ, YoungIS, PedersenBK, MøllerK, PietriS, CulcasiM (2014) On the antioxidant properties of erythropoietin and its association with the oxidative-nitrosative stress response to hypoxia in humans. Acta Physiol212, 175–187.
68.
GoodnoughLT (2007) Erythropoietin and iron-restricted erythropoiesis. Exp Hematol35, 167–172.
69.
BondWS, RexTS (2014) Evidence that erythropoietin modulates neuroinflammation though differential action on neurons, astrocytes and microglia. Front Immunol5, 523.
70.
ChongZZ, LinSH, KangJK, MaieseK (2003) Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. J Neurosci Res71, 659–669.
71.
ShangYC, ChongZZ, WangS, MaieseK (2012) Prevention of β-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging4, 187–201.
72.
McGeerEG, McGeerPL (2005) Abeta immunotherapy and other means to remove amyloid. Curr Drug Targets CNS Neurol Disord4, 569–573.
73.
BondWS, RexTS (2014) Evidence that erythropoietin modulates neuroinflammation through differential action on neurons, astrocytes, and microglia. Front Immunol5, 523.
74.
LiF, ChongZZ, MaieseK (2006) Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB. Curr Neurovasc Res3, 187–201.
75.
BrettschneiderJ, WidlK, EhrenreichH, RiepeM, TumaniH (2006) Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases. Neurosci Lett404, 347–351.
